The clinical-stage immunotherapy company Medicenna Therapeutics Corp. (OTC:MDNAF) is involved in the development of Superkines, and on April 24, it was in focus following a key announcement. The company announced yesterday that it would make the presentations for a pair of abstracts at the Annual Meeting of the American Society of Clinical Oncology that would be held from May 31 to June 4 in Chicago.
The abstracts would also include an oral podium presentation. The presence of a company at such important industry events provides industry stakeholders with a better idea of the work and offerings of the company. In the oral podium presentation, Medicenna Therapeutics would present fresh clinical data from the on-going Phase ABILITY study for MDNA11, a ‘beta enhanced not-alpha’ long-acting interlukin 2 super agonist. In the study, the product would be evaluated both in the form of monotherapy and also in combination with Keytruda for those who may be suffering from metastatic or advanced solid tumors.
In the news release, it was noted that the presentation would be titled “Results from an ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-Acting IL-2 Axagonist, in Patients with Advanced Solid Tumors.” It would be held during the ‘Developmental Therapeutics: Immunotherapy’ abstract session on June 3 between 11–30 AM and 2–30 PM CDT.
The second abstract from the company would provide details of new data analysis of bizaxofusp survival outcomes in comparison to a propensity-controlled external control arm in rBGM (nonresectable recurrent glioblastoma). The company stated that the second abstract was titled “Phase 2 Study of Bizaxofusp, an IL-4R Targeted Toxin Payload, in Nonresectable Recurrent GBM: Comparison of Overall Survival with Contemporaneous Eligibility-Matched and Propensity Score-Balanced External Control Arm.” It would be a poster session and take place on June 1.
